ipilimumab,nivolumab,
bms,delcath systems
['chopin']
$dcth positive initial results from chopin phase 1b trial, focus trial update and qol study presented at the 2022 asco annual meeting 45 seconds delayed.
Democratizing insights.

Not investment advice.